A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus
Background Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM) patients. Shrunken pore syndrome (SPS) is defined as eGFRcystatin C/eGFRcreatinine ratio <0.70 and predicts high CVD mortality. The Framingham Risk Score (FRS) is used to estimate an indiv...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Renal Failure |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2346267 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763050278617088 |
|---|---|
| author | Yan Yang Bixia Yang Shizhu Zhao Shusu Liu Hua Zhou Ning Xu Min Yang |
| author_facet | Yan Yang Bixia Yang Shizhu Zhao Shusu Liu Hua Zhou Ning Xu Min Yang |
| author_sort | Yan Yang |
| collection | DOAJ |
| description | Background Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM) patients. Shrunken pore syndrome (SPS) is defined as eGFRcystatin C/eGFRcreatinine ratio <0.70 and predicts high CVD mortality. The Framingham Risk Score (FRS) is used to estimate an individual’s 10-year CVD risk. This study investigated the association between FRS and eGFRcystatin C/eGFRcreatinine ratio in T2DM patients.Methods Patients aged 18-80 years who were newly diagnosed with T2DM were included in this retrospective study. Ordinal logistic regression analysis was used to investigate the association between risk factors of T2DM and FRS. A Generalized Linear Model was used to calculate odds ratios (OR) and 95% confidence intervals (CI).Results There were 270 patients included in the study. Only 27 patients (10%) met the diagnostic criteria of SPS. Ordinal logistic regression analysis showed that SPS was not correlated with FRS risk (OR = 1.99, 95%CI = 0.94–4.23, p = 0.07), whereas eGFRcystatin C/eGFRcreatinine (OR = 0.86, 95%CI = 0.77–0.97, p = 0.01) showed a significant negative association with FRS risk. Compared with eGFRcystatin C/eGFRcreatinine>0.85, eGFRcystatin C/eGFRcreatinine≤0.85 increased FRS risk (OR = 1.95, 95%CI = 1.18–3.21, p < 0.01). After adjustment for confounding factors, increased eGFRcystatin C/eGFRcreatinine ratio was associated with decreased FRS risk when considered as a continuous variable (OR = 0.87, 95%CI = 0.77–0.99, p = 0.03). The FRS risk in patients with eGFRcystatin C/eGFRcreatinine≤0.85 is 1.86 times higher than that in patients with eGFRcystatin C/eGFRcreatinine>0.85 (OR = 1.86, 95%CI = 1.08–3.21, p = 0.03).Conclusions In the current study, no significant association between SPS and FRS was identified. However, lower eGFRcystatin C/eGFRcreatinine and eGFRcystatin C/eGFRcreatinine≤0.85 were associated with a significantly increased CVD risk in T2DM. |
| format | Article |
| id | doaj-art-5a098d92d5fa4c318f593ade3c618b58 |
| institution | DOAJ |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-5a098d92d5fa4c318f593ade3c618b582025-08-20T03:05:33ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492024-12-0146210.1080/0886022X.2024.2346267A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitusYan Yang0Bixia Yang1Shizhu Zhao2Shusu Liu3Hua Zhou4Ning Xu5Min Yang6Department of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, ChinaDepartment of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, ChinaDepartment of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, ChinaDepartment of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, ChinaDepartment of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, ChinaDivision of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lund University, Lund, SwedenDepartment of Nephrology, The Third Affiliated Hospital of Soochow University, Changzhou, ChinaBackground Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes mellitus (T2DM) patients. Shrunken pore syndrome (SPS) is defined as eGFRcystatin C/eGFRcreatinine ratio <0.70 and predicts high CVD mortality. The Framingham Risk Score (FRS) is used to estimate an individual’s 10-year CVD risk. This study investigated the association between FRS and eGFRcystatin C/eGFRcreatinine ratio in T2DM patients.Methods Patients aged 18-80 years who were newly diagnosed with T2DM were included in this retrospective study. Ordinal logistic regression analysis was used to investigate the association between risk factors of T2DM and FRS. A Generalized Linear Model was used to calculate odds ratios (OR) and 95% confidence intervals (CI).Results There were 270 patients included in the study. Only 27 patients (10%) met the diagnostic criteria of SPS. Ordinal logistic regression analysis showed that SPS was not correlated with FRS risk (OR = 1.99, 95%CI = 0.94–4.23, p = 0.07), whereas eGFRcystatin C/eGFRcreatinine (OR = 0.86, 95%CI = 0.77–0.97, p = 0.01) showed a significant negative association with FRS risk. Compared with eGFRcystatin C/eGFRcreatinine>0.85, eGFRcystatin C/eGFRcreatinine≤0.85 increased FRS risk (OR = 1.95, 95%CI = 1.18–3.21, p < 0.01). After adjustment for confounding factors, increased eGFRcystatin C/eGFRcreatinine ratio was associated with decreased FRS risk when considered as a continuous variable (OR = 0.87, 95%CI = 0.77–0.99, p = 0.03). The FRS risk in patients with eGFRcystatin C/eGFRcreatinine≤0.85 is 1.86 times higher than that in patients with eGFRcystatin C/eGFRcreatinine>0.85 (OR = 1.86, 95%CI = 1.08–3.21, p = 0.03).Conclusions In the current study, no significant association between SPS and FRS was identified. However, lower eGFRcystatin C/eGFRcreatinine and eGFRcystatin C/eGFRcreatinine≤0.85 were associated with a significantly increased CVD risk in T2DM.https://www.tandfonline.com/doi/10.1080/0886022X.2024.2346267Type 2 diabetes mellitusframingham risk scoreshrunken pore syndromeeGFR |
| spellingShingle | Yan Yang Bixia Yang Shizhu Zhao Shusu Liu Hua Zhou Ning Xu Min Yang A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus Renal Failure Type 2 diabetes mellitus framingham risk score shrunken pore syndrome eGFR |
| title | A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus |
| title_full | A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus |
| title_fullStr | A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus |
| title_full_unstemmed | A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus |
| title_short | A lower eGFRcystatin C/eGFRcreatinine ratio is associated with greater cardiovascular risk (higher Framingham Risk Score) in Chinese patients with newly diagnosed type 2 diabetes mellitus |
| title_sort | lower egfrcystatin c egfrcreatinine ratio is associated with greater cardiovascular risk higher framingham risk score in chinese patients with newly diagnosed type 2 diabetes mellitus |
| topic | Type 2 diabetes mellitus framingham risk score shrunken pore syndrome eGFR |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2024.2346267 |
| work_keys_str_mv | AT yanyang aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT bixiayang aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT shizhuzhao aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT shusuliu aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT huazhou aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT ningxu aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT minyang aloweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT yanyang loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT bixiayang loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT shizhuzhao loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT shusuliu loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT huazhou loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT ningxu loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus AT minyang loweregfrcystatincegfrcreatinineratioisassociatedwithgreatercardiovascularriskhigherframinghamriskscoreinchinesepatientswithnewlydiagnosedtype2diabetesmellitus |